Service & Software
Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Research Report 2024
- Jan 20, 24
- ID: 14182
- Pages: 73
- Figures: 142
- Views: 22
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of ESR1 Mutated Metastatic Breast Cancer Diagnostics include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ESR1 Mutated Metastatic Breast Cancer Diagnostics.
Report Scope
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ESR1 Mutated Metastatic Breast Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
APIS Assay Technologies
lllumina, Inc.
GENCURIX
RainSure Scientific
NeoGenomics Laboratories
Sysmex Corporation
ASURAGEN,INC
Guardant Health
Segment by Type
NGS Based
PCR Based
Segment by Application
Hospital Associated Labs
lndependent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research lnstitutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics in Hospital Associated Labs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of ESR1 Mutated Metastatic Breast Cancer Diagnostics include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ESR1 Mutated Metastatic Breast Cancer Diagnostics.
Report Scope
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ESR1 Mutated Metastatic Breast Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
APIS Assay Technologies
lllumina, Inc.
GENCURIX
RainSure Scientific
NeoGenomics Laboratories
Sysmex Corporation
ASURAGEN,INC
Guardant Health
Segment by Type
NGS Based
PCR Based
Segment by Application
Hospital Associated Labs
lndependent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research lnstitutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NGS Based
1.2.3 PCR Based
1.3 Market by Application
1.3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Associated Labs
1.3.3 lndependent Diagnostic Laboratories
1.3.4 Diagnostic Imaging Centers
1.3.5 Cancer Research lnstitutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Perspective (2019-2030)
2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Growth Trends by Region
2.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Dynamics
2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
2.3.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
2.3.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Challenges
2.3.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue
3.1.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue
3.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio
3.4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue in 2023
3.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Type
4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Application
5.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
6.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 APIS Assay Technologies
11.1.1 APIS Assay Technologies Company Detail
11.1.2 APIS Assay Technologies Business Overview
11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.1.4 APIS Assay Technologies Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.1.5 APIS Assay Technologies Recent Development
11.2 lllumina, Inc.
11.2.1 lllumina, Inc. Company Detail
11.2.2 lllumina, Inc. Business Overview
11.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.2.4 lllumina, Inc. Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.2.5 lllumina, Inc. Recent Development
11.3 GENCURIX
11.3.1 GENCURIX Company Detail
11.3.2 GENCURIX Business Overview
11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.3.4 GENCURIX Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.3.5 GENCURIX Recent Development
11.4 RainSure Scientific
11.4.1 RainSure Scientific Company Detail
11.4.2 RainSure Scientific Business Overview
11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.4.4 RainSure Scientific Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.4.5 RainSure Scientific Recent Development
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Detail
11.5.2 NeoGenomics Laboratories Business Overview
11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.5.4 NeoGenomics Laboratories Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.5.5 NeoGenomics Laboratories Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.6.4 Sysmex Corporation Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 ASURAGEN,INC
11.7.1 ASURAGEN,INC Company Detail
11.7.2 ASURAGEN,INC Business Overview
11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.7.4 ASURAGEN,INC Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.7.5 ASURAGEN,INC Recent Development
11.8 Guardant Health
11.8.1 Guardant Health Company Detail
11.8.2 Guardant Health Business Overview
11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.8.4 Guardant Health Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.8.5 Guardant Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NGS Based
1.2.3 PCR Based
1.3 Market by Application
1.3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Associated Labs
1.3.3 lndependent Diagnostic Laboratories
1.3.4 Diagnostic Imaging Centers
1.3.5 Cancer Research lnstitutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Perspective (2019-2030)
2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Growth Trends by Region
2.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Dynamics
2.3.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
2.3.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
2.3.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Challenges
2.3.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue
3.1.1 Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue
3.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio
3.4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue in 2023
3.5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Type
4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Breakdown Data by Application
5.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
6.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
7.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 APIS Assay Technologies
11.1.1 APIS Assay Technologies Company Detail
11.1.2 APIS Assay Technologies Business Overview
11.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.1.4 APIS Assay Technologies Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.1.5 APIS Assay Technologies Recent Development
11.2 lllumina, Inc.
11.2.1 lllumina, Inc. Company Detail
11.2.2 lllumina, Inc. Business Overview
11.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.2.4 lllumina, Inc. Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.2.5 lllumina, Inc. Recent Development
11.3 GENCURIX
11.3.1 GENCURIX Company Detail
11.3.2 GENCURIX Business Overview
11.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.3.4 GENCURIX Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.3.5 GENCURIX Recent Development
11.4 RainSure Scientific
11.4.1 RainSure Scientific Company Detail
11.4.2 RainSure Scientific Business Overview
11.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.4.4 RainSure Scientific Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.4.5 RainSure Scientific Recent Development
11.5 NeoGenomics Laboratories
11.5.1 NeoGenomics Laboratories Company Detail
11.5.2 NeoGenomics Laboratories Business Overview
11.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.5.4 NeoGenomics Laboratories Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.5.5 NeoGenomics Laboratories Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.6.4 Sysmex Corporation Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 ASURAGEN,INC
11.7.1 ASURAGEN,INC Company Detail
11.7.2 ASURAGEN,INC Business Overview
11.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.7.4 ASURAGEN,INC Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.7.5 ASURAGEN,INC Recent Development
11.8 Guardant Health
11.8.1 Guardant Health Company Detail
11.8.2 Guardant Health Business Overview
11.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Introduction
11.8.4 Guardant Health Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
11.8.5 Guardant Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of NGS Based
Table 3. Key Players of PCR Based
Table 4. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2019-2024)
Table 8. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2025-2030)
Table 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Trends
Table 11. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
Table 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Challenges
Table 13. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
Table 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Players (2019-2024)
Table 16. Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics as of 2023)
Table 17. Ranking of Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Solution and Service
Table 21. Date of Enter into ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 25. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 27. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 29. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 31. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 46. APIS Assay Technologies Company Detail
Table 47. APIS Assay Technologies Business Overview
Table 48. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 49. APIS Assay Technologies Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 50. APIS Assay Technologies Recent Development
Table 51. lllumina, Inc. Company Detail
Table 52. lllumina, Inc. Business Overview
Table 53. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 54. lllumina, Inc. Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 55. lllumina, Inc. Recent Development
Table 56. GENCURIX Company Detail
Table 57. GENCURIX Business Overview
Table 58. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 59. GENCURIX Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 60. GENCURIX Recent Development
Table 61. RainSure Scientific Company Detail
Table 62. RainSure Scientific Business Overview
Table 63. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 64. RainSure Scientific Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 65. RainSure Scientific Recent Development
Table 66. NeoGenomics Laboratories Company Detail
Table 67. NeoGenomics Laboratories Business Overview
Table 68. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 69. NeoGenomics Laboratories Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 70. NeoGenomics Laboratories Recent Development
Table 71. Sysmex Corporation Company Detail
Table 72. Sysmex Corporation Business Overview
Table 73. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 74. Sysmex Corporation Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 75. Sysmex Corporation Recent Development
Table 76. ASURAGEN,INC Company Detail
Table 77. ASURAGEN,INC Business Overview
Table 78. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 79. ASURAGEN,INC Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 80. ASURAGEN,INC Recent Development
Table 81. Guardant Health Company Detail
Table 82. Guardant Health Business Overview
Table 83. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 84. Guardant Health Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 85. Guardant Health Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. NGS Based Features
Figure 4. PCR Based Features
Figure 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 7. Hospital Associated Labs Case Studies
Figure 8. lndependent Diagnostic Laboratories Case Studies
Figure 9. Diagnostic Imaging Centers Case Studies
Figure 10. Cancer Research lnstitutes Case Studies
Figure 11. ESR1 Mutated Metastatic Breast Cancer Diagnostics Report Years Considered
Figure 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Players in 2023
Figure 16. Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue in 2023
Figure 18. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 20. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 24. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2019-2030)
Figure 32. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 40. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 44. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. APIS Assay Technologies Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 47. lllumina, Inc. Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 48. GENCURIX Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 49. RainSure Scientific Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 50. NeoGenomics Laboratories Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 51. Sysmex Corporation Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 52. ASURAGEN,INC Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 53. Guardant Health Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Table 1. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of NGS Based
Table 3. Key Players of PCR Based
Table 4. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2019-2024)
Table 8. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2025-2030)
Table 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Trends
Table 11. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Drivers
Table 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Challenges
Table 13. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Restraints
Table 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Players (2019-2024)
Table 16. Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics as of 2023)
Table 17. Ranking of Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Solution and Service
Table 21. Date of Enter into ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 25. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 27. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 29. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 31. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 46. APIS Assay Technologies Company Detail
Table 47. APIS Assay Technologies Business Overview
Table 48. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 49. APIS Assay Technologies Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 50. APIS Assay Technologies Recent Development
Table 51. lllumina, Inc. Company Detail
Table 52. lllumina, Inc. Business Overview
Table 53. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 54. lllumina, Inc. Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 55. lllumina, Inc. Recent Development
Table 56. GENCURIX Company Detail
Table 57. GENCURIX Business Overview
Table 58. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 59. GENCURIX Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 60. GENCURIX Recent Development
Table 61. RainSure Scientific Company Detail
Table 62. RainSure Scientific Business Overview
Table 63. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 64. RainSure Scientific Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 65. RainSure Scientific Recent Development
Table 66. NeoGenomics Laboratories Company Detail
Table 67. NeoGenomics Laboratories Business Overview
Table 68. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 69. NeoGenomics Laboratories Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 70. NeoGenomics Laboratories Recent Development
Table 71. Sysmex Corporation Company Detail
Table 72. Sysmex Corporation Business Overview
Table 73. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 74. Sysmex Corporation Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 75. Sysmex Corporation Recent Development
Table 76. ASURAGEN,INC Company Detail
Table 77. ASURAGEN,INC Business Overview
Table 78. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 79. ASURAGEN,INC Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 80. ASURAGEN,INC Recent Development
Table 81. Guardant Health Company Detail
Table 82. Guardant Health Business Overview
Table 83. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product
Table 84. Guardant Health Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 85. Guardant Health Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. NGS Based Features
Figure 4. PCR Based Features
Figure 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 7. Hospital Associated Labs Case Studies
Figure 8. lndependent Diagnostic Laboratories Case Studies
Figure 9. Diagnostic Imaging Centers Case Studies
Figure 10. Cancer Research lnstitutes Case Studies
Figure 11. ESR1 Mutated Metastatic Breast Cancer Diagnostics Report Years Considered
Figure 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Players in 2023
Figure 16. Global Top ESR1 Mutated Metastatic Breast Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ESR1 Mutated Metastatic Breast Cancer Diagnostics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue in 2023
Figure 18. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 20. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 24. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2019-2030)
Figure 32. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 40. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Country (2019-2030)
Figure 44. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. APIS Assay Technologies Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 47. lllumina, Inc. Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 48. GENCURIX Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 49. RainSure Scientific Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 50. NeoGenomics Laboratories Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 51. Sysmex Corporation Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 52. ASURAGEN,INC Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 53. Guardant Health Revenue Growth Rate in ESR1 Mutated Metastatic Breast Cancer Diagnostics Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232